f17e12f0-54ed-4dc2-ab7e-22a1f90e1405
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 80
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.440
- HEDGEHOG_SIGNALING+0.350
- MYOGENESIS+0.330
- KRAS_SIGNALING_DN+0.290
- APICAL_JUNCTION+0.170
- APICAL_SURFACE+0.170
- NOTCH_SIGNALING+0.090
- PANCREAS_BETA_CELLS+0.090
- COAGULATION+0.080
- P53_PATHWAY+0.080
Top 10 suppressed
- E2F_TARGETS-0.550
- G2M_CHECKPOINT-0.530
- ANDROGEN_RESPONSE-0.460
- TNFA_SIGNALING_VIA_NFKB-0.450
- PROTEIN_SECRETION-0.420
- INTERFERON_GAMMA_RESPONSE-0.390
- MYC_TARGETS_V1-0.390
- ALLOGRAFT_REJECTION-0.380
- INFLAMMATORY_RESPONSE-0.360
- MTORC1_SIGNALING-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 8683d8f5-bba5-40a1-a460-ad6183d2302b | — | — | 0.906 |
| 2 | c2e34dda-0852-492e-9cde-3ff606259c12 | — | — | 0.875 |
| 3 | MNG559 | — | — | 0.864 |
| 4 | TCGA-W8-A86G-01A-21R-A36F-07 | — | A | 0.858 |
| 5 | MBCProject_3946_T4_RNA | — | A | 0.846 |
| 6 | 299f36bd-d9fd-41f5-8a29-3382e147a14f | — | — | 0.845 |
| 7 | SJEPD001534_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.839 |
| 8 | a528e2fc-f91a-4835-a0f6-0a49400a40a2 | — | — | 0.837 |
| 9 | R88 | — | — | 0.836 |
| 10 | 38aa467f-bd67-475e-9280-7e710bdc0cb3 | — | — | 0.835 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.440 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MYOGENESIS | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.290 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.090 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |
| COAGULATION | 0.080 | Binimetinib | — uncovered |
| P53_PATHWAY | 0.080 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.050 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.020 | Inavolisib | — uncovered |